May 8, 2007

DAVA Pharmaceuticals, Inc. announces the availability of AB-rated Cefdinir Capsules in 300 mg dosage strength and Cefdinir Powder for Oral Suspension in 125 mg/5 mL and 250 mg/5 mL dosage strengths.  Cefdinir Capsules and Cefdinir Powder for Oral Suspension will be distributed by DAVA.  DAVA’s Cefdinir products are bioequivalent to the branded product, Omnicef®. 

For more information about DAVA’s cefdinir product and a number to call with questions you may have about the product, please visit www.omnicef.com.

April 2, 2007
DAVA Pharmaceuticals, Inc. announced today that it has been granted a full release from liabilities related to the sale of IMPAX’ oxycodone and will continue to act as IMPAX’ exclusive distributor...more

August 21, 2006
DAVA Pharmaceuticals, Inc. announced today that it has completed the acquisition of STADA, Inc., which owns and operates the U.S. pharmaceutical business of German pharmaceutical leader STADA Arzneimittel AG...more

July 13, 2006
DAVA Pharmaceuticals, Inc. announced today that it has entered into an agreement with STADA Arzneimittel AG for the purchase of its wholly-owned subsidiary, STADA, Inc...more

December 7, 2005
DAVA Pharmaceuticals, Inc. is proud to announce the introduction of Oxycodone Hydrochloride Extended-Release Tablets (C-II) in 10, 20, 40, and 80 mg dosage strengths.  Oxycodone HCL ER is the AB-rated bio-equivalent version of Purdue Pharma L.P.’s OxyContin®...more

November 7, 2005
DAVA Pharmaceuticals, Inc. announced today that it has entered into a ten year agreement with IMPAX Laboratories, Inc. under which DAVA has been appointed the exclusive marketer and distributor of IMPAX’s oxycodone HCl extended-release tablets...more

November 4, 2005
DAVA Pharmaceuticals, Inc. announced today that it has completed the acquisition of VoSpire ER® pursuant to its Asset Purchase Agreement with Odyssey Pharmaceuticals, Inc., a subsidiary of Pliva d.d....more

September 28, 2005
DAVA Pharmaceuticals, Inc. announced today that it has entered into an agreement with Odyssey Pharmaceuticals, Inc., a subsidiary of PLIVA d.d., for the purchase of VoSpire ER®, the only albuterol extended release tablet indicated for the treatment of bronchospasm associated with reversible airway disease...more

August 30, 2005
DAVA Pharmaceuticals, Inc. announces its acceptance by the Department of Veterans Affairs’ for inclusion in the Federal Supply Program. DAVA is excited to be a part of this important program and looks forward to providing cost effective pharmaceutical products to well deserving veterans who have served their country.

May 23, 2005
DAVA Pharmaceuticals, Inc. introduces the first CLARITHROMYCIN Tablets (USP), Immediate Release (IR) & CLARITHROMYCIN Oral Suspension (USP) products. DAVA’s Clarithromycin products are the first available generic alternatives to Biaxin® Immediate Release.

April 14, 2005
DAVA Pharmaceuticals, Inc. and leading pharmaceutical industry logistics provider, DDN/Obergfel, LLC have entered into a multi-year logistics and distribution agreement. This agreement demonstrates DAVA’s continued focus on establishing itself as the generic pharmaceutical industry standard for customer service and supply chain management.